Aricò D - Search Results

1

Recurrent parathyromatosis in a patient with concomitant MEN1 and CASR gene alterations: Clinical management of a case report and literature review.

Sapuppo G, Giusti MA, Aricò D, Masucci R, Tavarelli M, Russo M, Pellegriti G. Sapuppo G, et al. Among authors: arico d. Front Endocrinol (Lausanne). 2023 Mar 14;14:1108278. doi: 10.3389/fendo.2023.1108278. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36998475 Free PMC article. Review.

2

Timing of examination affects reliability of 99mTc-methoxyisobutylisonitrile SPECT in distinguishing neoplastic from nonneoplastic brain hematomas.

Minutoli F, Angileri FF, Conti A, Herberg A, Aricò D, Baldari S, Cardali S, de Divitiis O, Germanò A, Baldari S. Minutoli F, et al. Among authors: arico d. J Nucl Med. 2005 Apr;46(4):574-9. J Nucl Med. 2005. PMID: 15809478 Free article. Clinical Trial.

3

Prostate Cancer Biochemical Recurrence Resulted Negative on [⁶⁸Ga]Ga-PSMA-11 but Positive on [¹⁸F]Fluoromethylcholine PET/CT.

Laudicella R, La Torre F, Davì V, Crocè L, Aricò D, Leonardi G, Russo S, Minutoli F, Burger IA, Baldari S. Laudicella R, et al. Among authors: arico d. Tomography. 2022 Sep 30;8(5):2471-2474. doi: 10.3390/tomography8050205. Tomography. 2022. PMID: 36287804 Free PMC article.

4

First case of ¹⁸F-choline uptake in acoustic schwannoma after stereotactic radiotherapy.

Arico' D, Giardina C, Tuscano C, Picone A, Militano V. Arico' D, et al. World J Nucl Med. 2019 Apr-Jun;18(2):187-188. doi: 10.4103/wjnm.WJNM_26_18. World J Nucl Med. 2019. PMID: 31040753 Free PMC article.

5

Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.

Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, Baio SM, Aricò D, Sansovini M, Paganelli G. Bartolomei M, et al. Among authors: arico d. Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1407-16. doi: 10.1007/s00259-009-1115-z. Epub 2009 Mar 25. Eur J Nucl Med Mol Imaging. 2009. PMID: 19319527 Clinical Trial.

6

Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC.

Sierra ML, Agazzi A, Bodei L, Pacifici M, Aricò D, De Cicco C, Quarna J, Sansovini M, De Simone M, Paganelli G. Sierra ML, et al. Among authors: arico d. Cancer Biother Radiopharm. 2009 Dec;24(6):659-65. doi: 10.1089/cbr.2009.0641. Cancer Biother Radiopharm. 2009. PMID: 20025545

7

Can Baseline [¹⁸F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study.

Bianchi A, De Rimini ML, Sciuto R, Annovazzi A, Di Traglia S, Bauckneht M, Lanfranchi F, Morbelli S, Nappi AG, Ferrari C, Rubini G, Panareo S, Urso L, Bartolomei M, D'Arienzo D, Valente T, Rossetti V, Caroli P, Matteucci F, Aricò D, Bombaci M, Caponnetto D, Bertagna F, Albano D, Dondi F, Gusella S, Spimpolo A, Carriere C, Balma M, Buschiazzo A, Gallicchio R, Storto G, Ruffini L, Scarlattei M, Baldari G, Cervino AR, Cuppari L, Burei M, Trifirò G, Brugola E, Zanini CA, Alessi A, Fuoco V, Seregni E, Deandreis D, Liberini V, Moreci AM, Ialuna S, Pulizzi S, Evangelista L. Bianchi A, et al. Among authors: arico d. Cancer Biother Radiopharm. 2023 May;38(4):256-267. doi: 10.1089/cbr.2022.0092. Epub 2023 Apr 25. Cancer Biother Radiopharm. 2023. PMID: 37098169

8

[⁶⁸Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [¹⁷⁷Lu]DOTATOC PRRT: The "Theragnomics" Concept.

Laudicella R, Comelli A, Liberini V, Vento A, Stefano A, Spataro A, Crocè L, Baldari S, Bambaci M, Deandreis D, Arico' D, Ippolito M, Gaeta M, Alongi P, Minutoli F, Burger IA, Baldari S. Laudicella R, et al. Among authors: arico d. Cancers (Basel). 2022 Feb 16;14(4):984. doi: 10.3390/cancers14040984. Cancers (Basel). 2022. PMID: 35205733 Free PMC article.

9

18 F-FET PET/CT in Calcifying Pseudoneoplasm of the Neuraxis : First Case.

Aricò D, Giacoppo G, Bambaci M, Marino L, Girlando A, Sortino G, Leone G, Fernandes B, Alì M, Evangelista L, Romano A. Aricò D, et al. Clin Nucl Med. 2024 Jun 1;49(6):e272-e273. doi: 10.1097/RLU.0000000000005197. Epub 2024 Mar 25. Clin Nucl Med. 2024. PMID: 38537205

10

The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistribution.

Aricò D, Grana CM, Vanazzi A, Ferrari M, Mallia A, Sansovini M, Martinelli G, Paganelli G, Cremonesi M. Aricò D, et al. Cancer Biother Radiopharm. 2009 Apr;24(2):271-5. doi: 10.1089/cbr.2008.0541. Cancer Biother Radiopharm. 2009. PMID: 19409050

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

60 results

Search Page